MarkWide Research

In-Vitro Colorectal Cancer Screening Tests Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 153
Delivery Format: PDF+ Excel

In-Vitro Colorectal Cancer Screening Tests Market size exceeded USD 765 million in 2020 and is anticipated to grow at a CAGR of over 5.9% between 2021 and 2027. Rising incidence of colorectal cancer (CRC) owing to various factors such as adoption of unhealthy lifestyle, diabetes, and aging population among others are stimulating the market growth. Moreover, growing awareness regarding in-vitro colorectal cancer screening tests and increasing use of biomarkers are expected to promote the market expansion.

However, several restraints associated with the use of in-vitro colorectal cancer screening tests such as lack of qualified staff and screening guidelines in developing regions may negatively impact the in-vitro colorectal cancer screening tests market growth. Inadequate reimbursement scenario pertaining to in-vitro colorectal cancer screening tests may further restrict the industry expansion. Shortage of trained medical workers in APAC region with the aging demographics and increased workload of physicians is poised to rise dramatically.

Additionally, dearth of favourable policies & campaigns for promoting the knowledge and use of in-vitro colorectal cancer screening tests is set to hamper the in-vitro colorectal cancer screening tests market progression. Furthermore, the U.S. FDA reviews and approves cancer screening tests, prescription drugs, and medical devices for colorectal cancer screening. These screening tests are mandated to obtain a premarket approval (PMA) before commercializing the product. The PMA approval refers to a complex process that requires safety & effectiveness data and has to undergo clinical trials study. The U.S. FDA regulates these tests to maintain regulatory standards.

The COVID-19 pandemic arose as an unparalleled health concern that has rendered negative impact on the in-vitro colorectal cancer screening tests market. The coronavirus outbreak affected global economy and multiple sectors. Revised standard operating protocols, travel restrictions, and social distancing measures further limited the hospital admissions related to non-COVID patients. Nationwide lockdowns, travel limitations, and emergencies declared in several countries disrupted the supply chain of healthcare products, further limiting the industry progression. Negligence towards non-COVID related medical operations hampered the use of in-vitro colorectal cancer screening tests globally.
However, several initiatives adopted by the public organizations to facilitate the colorectal cancer screening has benefitted the in-vitro colorectal cancer screening tests market demand. For instance, as per the Cancer.org, recent reports indicate that healthcare systems in California continued the supply of FIT kits in April and May of 2020. The FIT response rates remained high, despite the onset of the pandemic. Moreover, the European Cancer community mobilised its resources to assess, address, and mitigate the negative impact of COVID-19 crisis on colorectal cancer screening.

Affordable testing options with high clinical success rate will boost the industry growth

The fecal occult blood tests (FOBT) segment in the in-vitro colorectal cancer screening tests market was valued at around USD 625 million in 2020 led by the high preference for cost-effective fecal occult blood tests. Fecal occult blood tests (FOBT) uses the stool samples for detection of occult blood in the faeces.  The United States Preventative Services Task Force suggests colorectal cancer screening by the means of FOBT among other tests for individuals corresponding to 50-75 age group. FOBT is based on chemical reaction that detects the presence of blood in faeces and provides an inexpensive, simple, & accessible screening option. A clinical study that randomized 46,551 participants concluded that FOBT with rehydration reduced the 13-year cumulative mortality associated with CRC by 33%.

U.S. in-vitro colorectal cancer screening tests market is slated to reach around USD 392 million by 2027. This high revenue share is attributed to multiple factors including high prevalence of CRC, favourable reimbursement scenario, and increasing incidence of obesity across the country. Colorectal cancer is amongst the common cancers inflicting significant mortalities in the U.S. The American Cancer Society and the National Center for Health Statistics, in 2020, estimated that approximately 147,950 individuals were diagnosed with CRC. The incidence rate of CRC increased from 2012 to 2016, from 30 (per 100,000 individuals) to 45.7. These numbers are further estimated to rise with augmented incidence of obesity in the country. According to the Centers for Disease Control and Prevention (CDC), in 2017, obesity affects more than 18.5% of the children and adolescents in the U.S. Additionally, the current trends indicate around 33% increase in the prevalence of obesity in the coming years. These developments will expand the market size in the U.S. during the forecast period.

Key Players Covered:

Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation.

In-vitro Colorectal Cancer Screening Tests  Market Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

In-vitro colorectal cancer screening tests market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2030, for the following segments:

Market, By Test Type

  • Fecal occult blood test (FOBT)
    • Guaiac FOB stool test
    • Immuno-FOB agglutination test
    • Lateral flow immuno-FOB test
    • Immuno-FOB ELISA test
  • Biomarker test
    • Tumor M2-PK stool test
    • Transferrin assays
  • CRC DNA screening test
    • Methylated gene test
    • Panel DNA test

Market, By End-use

  • Hospital
  • Clinics
  • Diagnostic Laboratories
  • Others

The above information is provided for the following regions and countries:

Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa

Table of Contents

Chapter 1   Methodology

1.1    Market definition

1.2    Base estimates & working

1.3    Forecast parameters

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    In-vitro colorectal cancer screening tests industry 3600 synopsis, 2016 – 2027

2.1.1    Business trends

2.1.2    Test type trends

2.1.3    End-use trends

2.1.4    Regional trends

Chapter 3   In-Vitro Colorectal Cancer Screening Tests Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 – 2027 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers

3.3.1.1    Improvements in colorectal cancer screening through non-invasive methods

3.3.1.2    Advancements in the field of cancer diagnosis

3.3.1.3    Rising prevalence of colorectal cancer

3.3.1.4    Cost-efficient and high-speed DNA sequencing

3.3.2    Industry pitfalls & challenges

3.3.2.1    Lack of uniform cancer screening guidelines in Asia Pacific

3.3.2.2    Inadequate reimbursement coverage

3.3.2.3    Shortage of trained staff in developing regions

3.4    Growth potential analysis

3.4.1    By test type

3.4.2    By end-use

3.5    COVID-19 impact analysis

3.6    Porter’s analysis

3.7    Competitive landscape, 2020

3.7.1    Company matrix analysis, 2020

3.8    PESTEL analysis

Chapter 4   In-Vitro Colorectal Cancer Screening Tests Market, By Test Type

4.1    Key segment trends

4.2    Fecal occult blood test (FOBT)

4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.2    Guaiac FOB stool test

4.2.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.3    Immuno-FOB agglutination test

4.2.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.4    Lateral flow immuno-FOB test

4.2.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.5    Immuno-FOB ELISA test

4.2.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.3    Biomarker test

4.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.2    Tumor M2-PK stool test

4.3.2.1.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.3    Transferrin assays

4.3.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.4    CRC DNA screening test

4.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.4.2    Methylated gene test

4.4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.4.3    Panel DNA test

4.4.3.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 5   In-Vitro Colorectal Cancer Screening Tests Market, By End-use

5.1    Key segment trends

5.2    Hospitals

5.2.1    Market size, by region, 2016 – 2027 (USD Million)

5.3    Clinics

5.3.1    Market size, by region, 2016 – 2027 (USD Million)

5.4    Diagnostic laboratories

5.4.1    Market size, by region, 2016 – 2027 (USD Million)

5.5    Others

5.5.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 6   In-Vitro Colorectal Cancer Screening Tests Market, By Region

6.1    Key regional trends

6.2    North America

6.2.1    Market size, by country, 2016 – 2027 (USD Million)

6.2.2    Market size, by test type, 2016 – 2027 (USD Million)

6.2.2.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.2.2.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.2.2.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.2.3    Market size, by end-use, 2016 – 2027 (USD Million)

6.2.4    U.S.

6.2.4.1    Market size, by test type, 2016 – 2027 (USD Million)

6.2.4.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.2.4.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.2.4.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.2.4.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.2.5    Canada

6.2.5.1    Market size, by test type, 2016 – 2027 (USD Million)

6.2.5.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.2.5.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.2.5.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.2.5.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.3    Europe

6.3.1    Market size, by country, 2016 – 2027 (USD Million)

6.3.2    Market size, by test type, 2016 – 2027 (USD Million)

6.3.2.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.3.2.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.3.2.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.3.3    Market size, by end-use, 2016 – 2027 (USD Million)

6.3.4    Germany

6.3.4.1    Market size, by test type, 2016 – 2027 (USD Million)

6.3.4.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.3.4.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.3.4.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.3.4.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.3.5    UK

6.3.5.1    Market size, by test type, 2016 – 2027 (USD Million)

6.3.5.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.3.5.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.3.5.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.3.5.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.3.6    France

6.3.6.1    Market size, by test type, 2016 – 2027 (USD Million)

6.3.6.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.3.6.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.3.6.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.3.6.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.3.7    Spain

6.3.7.1    Market size, by test type, 2016 – 2027 (USD Million)

6.3.7.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.3.7.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.3.7.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.3.7.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.3.8    Italy

6.3.8.1    Market size, by test type, 2016 – 2027 (USD Million)

6.3.8.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.3.8.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.3.8.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.3.8.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.4    Asia Pacific

6.4.1    Market size, by country, 2016 – 2027 (USD Million)

6.4.2    Market size, by test type, 2016 – 2027 (USD Million)

6.4.2.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.4.2.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.4.2.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.4.3    Market size, by end-use, 2016 – 2027 (USD Million)

6.4.4    China

6.4.4.1    Market size, by test type, 2016 – 2027 (USD Million)

6.4.4.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.4.4.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.4.4.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.4.4.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.4.5    Japan

6.4.5.1    Market size, by test type, 2016 – 2027 (USD Million)

6.4.5.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.4.5.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.4.5.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.4.5.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.4.6    India

6.4.6.1    Market size, by test type, 2016 – 2027 (USD Million)

6.4.6.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.4.6.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.4.6.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.4.6.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.4.7    Australia

6.4.7.1    Market size, by test type, 2016 – 2027 (USD Million)

6.4.7.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.4.7.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.4.7.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.4.7.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.4.8    South Korea

6.4.8.1    Market size, by test type, 2016 – 2027 (USD Million)

6.4.8.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.4.8.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.4.8.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.4.8.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.5    Latin America

6.5.1    Market size, by country, 2016 – 2027 (USD Million)

6.5.2    Market size, by test type, 2016 – 2027 (USD Million)

6.5.2.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.5.2.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.5.2.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

6.5.4    Brazil

6.5.4.1    Market size, by test type, 2016 – 2027 (USD Million)

6.5.4.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.5.4.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.5.4.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.5.4.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.5.5    Mexico

6.5.5.1    Market size, by test type, 2016 – 2027 (USD Million)

6.5.5.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.5.5.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.5.5.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.5.5.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.5.6    Argentina

6.5.6.1    Market size, by test type, 2016 – 2027 (USD Million)

6.5.6.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.5.6.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.5.6.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.5.6.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.6    Middle East and Africa

6.6.1    Market size, by country, 2016 – 2027 (USD Million)

6.6.2    Market size, by test type, 2016 – 2027 (USD Million)

6.6.2.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.6.2.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.6.2.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

6.6.4    South Africa

6.6.4.1    Market size, by test type, 2016 – 2027 (USD Million)

6.6.4.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.6.4.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.6.4.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.6.4.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.6.5    Saudi Arabia

6.6.5.1    Market size, by test type, 2016 – 2027 (USD Million)

6.6.5.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.6.5.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.6.5.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.6.5.2    Market size, by end-use, 2016 – 2027 (USD Million)

6.6.6    UAE

6.6.6.1    Market size, by test type, 2016 – 2027 (USD Million)

6.6.6.1.1    Market size, by fecal occult blood test (FOBT), 2016 – 2027 (USD Million)

6.6.6.1.2    Market size, by biomarker test, 2016 – 2027 (USD Million)

6.6.6.1.3    Market size, by CRC DNA screening test, 2016 – 2027 (USD Million)

6.6.6.2    Market size, by end-use, 2016 – 2027 (USD Million)

Chapter 7   Company Profiles

7.1    Competitive dashboard, 2020

7.2    Abbott Molecular

7.2.1    Business overview

7.2.2    Financial data

7.2.3    Product landscape

7.2.4    Strategic outlook

7.2.5    SWOT analysis

7.3    Epigenomics AG

7.3.1    Business overview

7.3.2    Financial data

7.3.3    Product landscape

7.3.4    Strategic outlook

7.3.5    SWOT analysis

7.4    Sysmex Corporation

7.4.1    Business overview

7.4.2    Financial data

7.4.3    Product landscape

7.4.4    Strategic outlook

7.4.5    SWOT analysis

7.5    Eiken Chemical

7.5.1    Business overview

7.5.2    Financial data

7.5.3    Product landscape

7.5.4    Strategic outlook

7.5.5    SWOT analysis

7.6    Quest Diagnostics

7.6.1    Business overview

7.6.2    Financial data

7.6.3    Product landscape

7.6.4    Strategic outlook

7.6.5    SWOT analysis

7.7    OncoCyte Corporation-Bio time

7.7.1    Business overview

7.7.2    Financial data

7.7.3    Product landscape

7.7.4    Strategic outlook

7.7.5    SWOT analysis

7.8    BioMarCare Technologies

7.8.1    Business overview

7.8.2    Financial data

7.8.3    Product landscape

7.8.4    Strategic outlook

7.8.5    SWOT analysis

7.9    Novigenix

7.9.1    Business overview

7.9.2    Financial data

7.9.3    Product landscape

7.9.4    Strategic outlook

7.9.5    SWOT analysis

7.10    Randox Laboratories

7.10.1    Business overview

7.10.2    Financial data

7.10.3    Product landscape

7.10.4    Strategic outlook

7.10.5    SWOT analysis

7.11    Exact Sciences Corporation

7.11.1    Business overview

7.11.2    Financial data

7.11.3    Product landscape

7.11.4    Strategic outlook

7.11.5    SWOT analysis

7.12    Immunostics

7.12.1    Business overview

7.12.2    Financial data

7.12.3    Product landscape

7.12.4    Strategic outlook

7.12.5    SWOT analysis

7.13    R-Biopharm Incorporation

7.13.1    Business overview

7.13.2    Financial data

7.13.3    Product landscape

7.13.4    Strategic outlook

7.13.5    SWOT analysis

Segmentation

Market, By Test Type

  • Fecal occult blood test (FOBT)
    • Guaiac FOB stool test
    • Immuno-FOB agglutination test
    • Lateral flow immuno-FOB test
    • Immuno-FOB ELISA test
  • Biomarker test
    • Tumor M2-PK stool test
    • Transferrin assays
  • CRC DNA screening test
    • Methylated gene test
    • Panel DNA test

Market, By End-use

  • Hospital
  • Clinics
  • Diagnostic Laboratories
  • Others

Major Companies

  • Abbott Molecular
  • Epigenomics AG
  • Novigenix
  • Sysmex Corporation
  • Eiken Chemical
  • Quest Diagnostics
  • BioMarCare Technologies
  • Randox Laboratories
  • OncoCyte Corporation-Bio time
  • Exact Sciences Corporation
  • Immunostics
  • Others

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF